Operators evaluating the mid-Atlantic keep asking us the same question: Maryland or Virginia? The honest answer is both — but the playbook for each is fundamentally different, and the data from Maryland's first two years tells you exactly why.
Maryland by the Numbers
Maryland launched adult-use sales on July 1, 2023. Two years in, the picture is clear:
- $700M+ in adult-use revenue in the first 18 months
- 100+ licensed dispensaries operating across the state
- Price compression of 35-40% from initial retail pricing as supply caught up with demand
- Medical-to-adult-use conversion rate hovering around 70% — most medical dispensaries added adult-use endorsements successfully
The market is real, the revenue is real, and the margins are settling into sustainable territory. But "sustainable" looks very different from "early-stage windfall," and that gap is where operators either thrive or bleed cash.
What Worked in Maryland
1. Medical Incumbents Who Moved Fast
The dispensaries that added adult-use endorsements within the first 90 days captured disproportionate market share. The ones that waited for "the market to stabilize" lost their local advantage to competitors who didn't hesitate.
2. Operators Who Priced for Volume, Not Margin
The winning retail strategy in Maryland was aggressive opening pricing to capture customer base, then gradually increasing as loyalty locked in. Operators who tried to maintain 50%+ gross margins from day one were undercut within weeks.
3. Supply Chain Verticals
Cultivator-processor-dispensary operators controlled their cost structure in a way that pure-play retailers couldn't match. When wholesale prices dropped 30%, vertically-integrated operators still had margin. Everyone else was squeezed.
The lesson from Maryland isn't "get in early" — it's "build for the margin structure that exists at maturity, not the one that exists at launch."
What Didn't Work
1. Over-Reliance on Tourism Proximity
Several operators built financial models around DC and Baltimore tourist traffic. The reality: locals drive 80%+ of cannabis revenue. Tourist-dependent dispensaries saw 30-40% seasonal variance that their pro formas never modeled.
2. Me-Too Brand Strategies
When every dispensary on a corridor stocks the same 15 brands, differentiation becomes price — and price wars destroy margins faster than any regulatory change. The operators winning in Maryland invested in exclusive brand relationships and private-label products.
3. Undercapitalized Fast Entries
Operators who raised just enough to open their doors — but not enough to sustain 12-18 months of operating losses during the ramp — are the ones closing or selling at discounts. The market's maturation curve is steeper than anyone's pro forma predicted.
Maryland had a 2-year head start and a medical infrastructure that could convert. Virginia is building from a thinner medical base but with more deliberate licensing controls. The comparison matters because it tells you what Maryland's mistakes look like when you still have time to avoid them.
Virginia vs. Maryland: The Operator's Decision Matrix
| Factor | Maryland | Virginia |
|---|---|---|
| Market maturity | Established, 2 years in | Pre-launch, 2026 |
| License availability | Limited new licenses | First wave, ~350 retail |
| Entry cost | Acquisition premium | Application cost only |
| Revenue timeline | Immediate (acquire) | 12-18 months to positive |
| Regulatory risk | Low (stable framework) | Medium (veto history) |
The Dual-Market Play
The smartest operators we're working with aren't choosing Maryland or Virginia — they're building for both. The playbook looks like this:
- Virginia application as the first-mover bet. Lower cost, higher upside, higher timeline risk.
- Maryland acquisition or partnership as the cash-flow anchor. Proven revenue, lower upside, lower risk.
- Shared supply chain — cultivation and processing in one jurisdiction serving both markets — is the margin multiplier that makes the dual-market model work.
This isn't theoretical. We're actively advising three operators on this exact structure. The regulatory nuances between the two states matter at the license-application level, but the strategic logic is the same: Virginia for growth, Maryland for cash, shared infrastructure for margin.
Evaluating mid-Atlantic options?
We've walked operators through this decision dozens of times. The right answer depends on your capital, timeline, and risk tolerance — not on which state has better headlines.
Start a Conversation →The Bottom Line
Maryland proves the mid-Atlantic cannabis market works. The data is in — revenue, margins at maturity, customer behavior, competitive dynamics. Virginia offers the next opening, with different timing economics and a different risk profile. The operators who understand both markets are the ones building the most resilient businesses.
If you're weighing Maryland, Virginia, or both, let's talk.